Drug Safety Biomarker Services

The pharmaceutical industry continues to explore new methods to prevent costly and unforeseen safety issues during drug development. Biomarkers are increasingly viewed by the FDA as a means for providing toxicity information earlier in drug development. Safety biomarkers should be quantitative, highly specific, and sensitive in order to provide insight into onset, severity, and recovery of toxicities. Nextcea specializes in the discovery, development, and GLP/non-GLP application of drug safety biomarkers to reduce late-stage drug attrition by guiding clinical development and meeting regulatory expectations.


Tengstrand E, Miwa G, Hsieh F. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities. Exper Opin. Drug Metab. Toxicol. 2010; 6(5): 555-570.


*2 Tengstrand E, Miwa G, Hsieh F. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities. Exper Opin. Drug Metab. Toxicol. 2010; 6(5): 555-570


*Nextcea Publications

About Nextcea, Inc.

Nextcea, Inc. is a drug development service company dedicated to optimizing efficacy and minimizing toxicity in all phases of drug development. Nextcea integrates cross-species biomarker studies with traditional PK/PD and TK/TD. In-house platforms include HPLC/UPLC coupled to mass spectrometry LC-MS and LC-MS/MS (API-6500s and and TripleTOF 6600).

Nextcea, Inc.
500 W. Cummings Park, Suite 4550
Woburn, MA 01801
phone: 800-225-1645
Inform@nextcea.com

Frank Hsieh
frank.hsieh@nextcea.com

Hirohide Mimura (三村英英):
hiro.mimura@nextcea.com